Skip to main content
Journal cover image

Biomarkers.

Publication ,  Journal Article
Smith, PJ; Johnson, KG; Roth, HL; Potter, GG; Patillo, S; Lin, WJ; Song, AJ; Berger, M; O'Brien, RJ; Liu, A; Lutz, MW; Luo, S; Bozoki, A ...
Published in: Alzheimers Dement
December 2025

BACKGROUND: Cerebrospinal fluid (CSF) biomarkers for Alzheimer's Disease and Related Dementias (ADRD) have gained widespread usage in clinical diagnosis and treatment, but their utility among middle-aged individuals has yet to be fully elucidated. We examined ADRD biomarker profiles across the lifespan among adults in the Duke-UNC ADRC cohort. METHOD: We examined demographic and clinical correlates of ADRD biomarker profiles among participants enrolled in the Duke-UNC ADRC (n = 243) who underwent CSF biomarker assessments (n = 162). CSF markers included Aβ42/40, phosphorylated tau (p-tau181), and neurofilament light (NfL). We also characterized biomarker positive individuals using a cutoff of AΒ42/40 ≤ 0.062. Individuals with at least one APOE risk allele were considered to have elevated APOE risk. Linear regression models were used to characterize correlates of ADRD biomarkers, controlling for age, education, gender, race, and APOE genotype. RESULT: Participants ranged from 28 to 80 years of age (mean = 59.8 years [SD = 11.4]), were mostly female (n = 111, 69%) and white (n = 129, 20%), nearly half had ≥ one APOE risk allele (48%), and 36 (27%) were biomarker positive. Age and APOE status were the most robust correlates of biomarker levels. Older age associated with lower AΒ42/40 (B = -0.44, p <.001), and greater p-tau181 (B = 0.53, p <.001), and NfL (B = 0.30, p <.001). APOE status similarly associated with lower AΒ42/40 (B = -0.45, p <.001), and greater p-tau181 (B = 0.24, p = .001). Visual inspection of ADRD biomarker levels suggested that AΒ42/40 levels approached or exceeded clinical thresholds in some individuals beginning in midlife. CONCLUSION: Age and APOE risk robustly associate with ADRD biomarkers and this association may begin in middle-age.

Duke Scholars

Published In

Alzheimers Dement

DOI

EISSN

1552-5279

Publication Date

December 2025

Volume

21 Suppl 2

Issue

Suppl 2

Start / End Page

e098089

Location

United States

Related Subject Headings

  • tau Proteins
  • Peptide Fragments
  • Neurofilament Proteins
  • Middle Aged
  • Male
  • Humans
  • Geriatrics
  • Female
  • Cohort Studies
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smith, P. J., Johnson, K. G., Roth, H. L., Potter, G. G., Patillo, S., Lin, W. J., … Whitson, H. (2025). Biomarkers. Alzheimers Dement, 21 Suppl 2(Suppl 2), e098089. https://doi.org/10.1002/alz70856_098089
Smith, Patrick J., Kim G. Johnson, Heidi L. Roth, Guy G. Potter, Sara Patillo, Weili J. Lin, Allen J. Song, et al. “Biomarkers.Alzheimers Dement 21 Suppl 2, no. Suppl 2 (December 2025): e098089. https://doi.org/10.1002/alz70856_098089.
Smith PJ, Johnson KG, Roth HL, Potter GG, Patillo S, Lin WJ, et al. Biomarkers. Alzheimers Dement. 2025 Dec;21 Suppl 2(Suppl 2):e098089.
Smith, Patrick J., et al. “Biomarkers.Alzheimers Dement, vol. 21 Suppl 2, no. Suppl 2, Dec. 2025, p. e098089. Pubmed, doi:10.1002/alz70856_098089.
Smith PJ, Johnson KG, Roth HL, Potter GG, Patillo S, Lin WJ, Song AJ, Berger M, O’Brien RJ, Liu A, Lutz MW, Luo S, Bozoki A, Welsh-Bohmer KA, Garden GA, Whitson H. Biomarkers. Alzheimers Dement. 2025 Dec;21 Suppl 2(Suppl 2):e098089.
Journal cover image

Published In

Alzheimers Dement

DOI

EISSN

1552-5279

Publication Date

December 2025

Volume

21 Suppl 2

Issue

Suppl 2

Start / End Page

e098089

Location

United States

Related Subject Headings

  • tau Proteins
  • Peptide Fragments
  • Neurofilament Proteins
  • Middle Aged
  • Male
  • Humans
  • Geriatrics
  • Female
  • Cohort Studies
  • Biomarkers